Evaluation of Glypican-3 expression in benign and malignant salivary gland tumors.
ACC
GPC3
MEC
PA
Salivary gland tumor
Journal
Journal of oral biology and craniofacial research
ISSN: 2212-4268
Titre abrégé: J Oral Biol Craniofac Res
Pays: Netherlands
ID NLM: 101619156
Informations de publication
Date de publication:
Historique:
received:
29
12
2017
revised:
24
07
2018
accepted:
06
09
2018
entrez:
9
10
2018
pubmed:
9
10
2018
medline:
9
10
2018
Statut:
ppublish
Résumé
Glypican-3 (GPC3) is involved in regulation of cell proliferation and morphogenesis. It is abundant in embryonic tissue, but limited in most adult tissues. GPC3 deletion or mutation can disturb the balance between cell apoptosis and proliferation, which may result in tumorigenesis. This study aimed to investigate the GPC3 expression in salivary gland tumors (SGTs) and the adjacent non-neoplastic tissues. This study reviewed 50 samples of salivary tumors from the archive of Khalili Hospital, Shiraz, Iran, including 17 cases of pleomorphic adenoma (PA), 16 cases of mucoepidermoid carcinoma (MEC), and 17 cases of adenoid cystic carcinoma (ACC); as well as a control group of 23 cases of normal salivary gland tissues. GPC3 expression was investigated through immunohistochemistry. GPC3 expression was significantly higher in malignant tumors (MEC and ACC) than in PA, and higher in PA than in the normal salivary glands (P < 0.001). The expression intensity was moderate to strong in malignant tumors and weak to moderate in benign tumors. No strong positivity was observed in normal salivary gland tissues (P < 0.001). Nor was any association detected between the GPC3 expression and intensity with the clinicopathologic parameters. Although GPC3 overexpression was observed at the protein level in SGTs, and its expression was not related with the clinicopathologic factors, the potential use of GPC3 for diagnostic, therapeutic, and prognostic purposes requires further investigations.
Identifiants
pubmed: 30294537
doi: 10.1016/j.jobcr.2018.09.002
pii: S2212-4268(17)30291-9
pmc: PMC6170252
doi:
Types de publication
Journal Article
Langues
eng
Pagination
63-66Références
BMC Cancer. 2014 Aug 29;14:631
pubmed: 25168166
Cancer Res. 1997 Nov 15;57(22):5179-84
pubmed: 9371521
Oncogene. 2001 Nov 1;20(50):7408-12
pubmed: 11704870
Tumour Biol. 2015 Jun;36(6):4671-9
pubmed: 25619476
Clin Cancer Res. 2005 Nov 15;11(22):8079-88
pubmed: 16299239
Asian Pac J Cancer Prev. 2013;14(1):27-30
pubmed: 23534736
Cancer Sci. 2008 Jun;99(6):1139-46
pubmed: 18429952
Clin Cancer Res. 2004 Oct 1;10(19):6612-21
pubmed: 15475451
Lab Invest. 2006 Dec;86(12):1272-84
pubmed: 17117158
CA Cancer J Clin. 2005 Jul-Aug;55(4):242-58; quiz 261-2, 264
pubmed: 16020425
Turk Patoloji Derg. 2018;34(2):158-164
pubmed: 29383694
Am J Clin Pathol. 2012 Jun;137(6):937-45
pubmed: 22586053
J Cell Biol. 2003 Nov 10;163(3):625-35
pubmed: 14610063
Am J Respir Cell Mol Biol. 2003 Dec;29(6):694-701
pubmed: 12816733
Head Neck Pathol. 2009 Mar;3(1):69-77
pubmed: 20596994
Int J Clin Pharmacol Ther. 1998 Jan;36(1):58-60
pubmed: 9476151
Breast Cancer Res Treat. 2003 Jul;80(2):221-32
pubmed: 12908826
Am J Clin Pathol. 2008 Jun;129(6):899-906
pubmed: 18480006
J Biol Chem. 2005 Jan 21;280(3):2116-25
pubmed: 15537637
Tumour Biol. 2012 Oct;33(5):1767-76
pubmed: 22684773
Can J Gastroenterol. 2013 Jun;27(6):351-63
pubmed: 23781519
Biomarkers. 2013 Feb;18(1):1-9
pubmed: 22931385
Cancer Sci. 2009 Aug;100(8):1403-7
pubmed: 19496787
Int J Cancer. 2000 Sep 20;89(5):418-22
pubmed: 11008203
J Clin Invest. 2001 Aug;108(4):497-501
pubmed: 11518720
Cancer Res. 1999 Feb 15;59(4):807-10
pubmed: 10029067